ProSharesLeveraged EquityBIB · Nasdaq

ProShares Ultra Nasdaq Biotechnology (BIB)

Loading NAV history…

ProShares Ultra Nasdaq Biotechnology

Fund only: no comparison series covers this fund's history.

Five years of daily closes. Risk-free rate 4% a year.

Trailing returns compared with benchmark
Period	1M	3M	6M	YTD	1Y	3YCAGR	5YCAGR	10YCAGR	LaunchCAGR
ETF	+0.3%	+32.8%	+39.6%	+37.6%	+86.2%	+29.6%	+1.3%	+9.6%	+18.0%
Leveraged Equity average	-3.1%	-7.2%	21.2%	13.2%	32.3%	25.3%	6.1%	9.5%	-5.3%
Difference	+3.4%	+40.0%	+18.4%	+24.4%	+53.9%	+4.3%	-4.8%	+0.1%	+23.2%

Holdings

The 8 largest positions make up 25.7% of the fund.

Largest holdings by weight
Ticker	Holding	Weight
IQMM	ProShares GENIUS Money Market ETF	4.94%
AMGN	Amgen Inc	4.72%
VRTX	Vertex Pharmaceuticals Inc	4.50%
GILD	Gilead Sciences Inc	4.02%
REGN	Regeneron Pharmaceuticals Inc	2.90%
MRNA	Moderna Inc	1.96%
RVMD	Revolution Medicines Inc Ordinary Shares	1.54%
ILMN	Illumina Inc	1.14%

Weighted averages of what the fund holds.

Share of the equity the fund holds.

Share of the bonds by rating.

Prices and returns as of 11 Sept 2026; total return with distributions reinvested, before brokerage and taxes. Not investment advice.

Other ETFs in the Leveraged Equity category.